a:3:{i:0;s:27:"http://truvadapreprems.com/";i:1;s:46126:"<!DOCTYPE html>
<!--[if lt IE 7]> <html class="no-js ie6" lang="en"> <![endif]-->
<!--[if IE 7]>    <html class="no-js ie7" lang="en"> <![endif]-->
<!--[if IE 8]>    <html class="no-js ie8" lang="en"> <![endif]-->
<!--[if gt IE 8]><!--> <html lang="en"> <!--<![endif]-->
<head>


<!-- partial view that will contain meta data, css files and modernizr -->
<meta charset="utf-8" />
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" />
    
<title>TRUVADA for a PrEP Indication | Official REMS Site</title>

<!-- Mobile viewport optimized -->
<meta name="viewport" content="width=device-width">
<meta name="keywords" content="TRUVADA for prep, hiv prevention strategy" />
<meta name="description" content="The official REMS site for TRUVADA for a PrEP indication." />
<link type="image/x-icon" href="../favicon.ico" rel="shortcut icon" />

    <link href="/Content/css/styles.css" rel="stylesheet" type="text/css" />

<!-- Begin DH Picture -->
<script type="text/javascript">
	var dhPictureConfig = { branding: 'b', platform: 'd' };
	var DHPIC = { 'trackEvent': function (s) { }, 'trackEntry': function (s) { } };
	(function () {
		var script = document.createElement("script");
		var s = document.getElementsByTagName("script")[0];
		script.async = true;
		script.src = "//gilead-picture.digitashealth.com/picture-bundle.min.js";
		s.parentNode.insertBefore(script, s);
	} ());
</script>
<!-- End DH Picture -->

    <!-- Any custom scripts or styles that should go in the header -->
    
</head>

<body>
    
    <!-- Start Google Analytics Tag -->
    <script type="text/javascript">
        var _gaq = _gaq || [];
        _gaq.push(['_setAccount', 'UA-31509379-1']);
        _gaq.push(['_trackPageview']);
        setTimeout("_gaq.push(['_trackEvent', 'Adjusted Time', 'Stayed','30 Seconds', 1,true])", 30000);
        setTimeout("_gaq.push(['_trackEvent', 'Adjusted Time', 'Stayed','60 Seconds', 1,true])", 60000);

        (function () {
            var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
            ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
            var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);
        })();
    </script>
        <!-- Generate DoubleClick Floodlight Tag -->

                <!-- 
                    Start of DoubleClick Floodlight Tag
                    Activity name of this tag: HomePage
                    Creation Date: 06/04/2012 
                --> 
                    <script type="text/javascript"> 
                        var axel = Math.random() + ""; 
                        var a = axel * 10000000000000;
                        document.write('<iframe src="http://fls.doubleclick.net/activityi;src=3471255;type=truva807;cat=truva844;ord=1;num=' + a + '?" width="1" height="1" frameborder="0" style="display:none"></iframe>'); 
                    </script> 
                    <noscript> 
                        <iframe src="http://fls.doubleclick.net/activityi;src=3471255;type=truva807;cat=truva844;ord=1;num=1?" width="1" height="1" frameborder="0" style="display:none"></iframe> 
                    </noscript> 
                <!-- End of DoubleClick Floodlight Tag: Please do not remove -->
    
    <!-- MAIN CONTENT -->
    


<!-- main container -->
<div id="siteContainer">
    <!-- HEADER: Logo and Links -->
<div id="header">
    <div id="linkscontainer">
        <ul id="toplinks">
            <li><a href="/online-training">REMS Information</a></li>
            <li><a id="prescLink" class="dhpic" href="http://www.gilead.com/~/media/Files/pdfs/medicines/hiv/truvada/truvada_pi.pdf" target="_blank">Prescribing Information and Medication Guide</a></li>
            <li id="isiLink" class="dhpic last"><a href="/truvadaprep-safety-profile">Important Safety Information including BOXED WARNING</a></li>
        </ul>
    </div>
    <div id="logo">
        <a id="truvada-logo" href="/" title="TRUVADA for a PrEP Indication">
            <img src="/Content/img/global/lgo_truvada.png" width="218" height="65" alt="Truvada Logo" />
        </a>
    </div>    
</div>
    <!-- TOP MENU -->
    <div id="topMenu">
        <div id='menuItems'>
<div class='navSection ' style='width:195px'><a href='/pre-exposure-prophylaxis'><span class='menuTitle ' >PROPHYLAXIS THERAPY</span></a><ul style='display: none;'><li class='subMenuTitle '><a href='/pre-exposure-prophylaxis'><span><nobr>TRUVADA for a PrEP Indication</nobr></span></a></li><li class='subMenuTitle '><a href='/comprehensive-hiv-management'><span><nobr>Comprehensive Management</nobr></span></a></li><li class='subMenuTitle '><a href='/truvadaprep-safety-profile'><span>Important Safety Information</span></a></li></ul></div>
<div class='navSection ' style='width:165px'><a href='/truvadaprep-prescriber-checklist'><span class='menuTitle ' >STARTING INDIVIDUALS</span></a><ul style='display: none;'><li class='subMenuTitle '><a href='/truvadaprep-prescriber-checklist'><span>Checklist for Prescribers</span></a></li><li class='subMenuTitle '><a href='/truvadaprep-agreement-form'><span>Agreement Form</span></a></li></ul></div>
<div class='navSection ' style='width:205px'><a href='/truvadaprep-resources'><span class='menuTitle ' >SUPPORT</span></a><ul style='display: none;'><li class='subMenuTitle '><a href='/truvadaprep-resources'><span>REMS Materials</span></a></li><li class='subMenuTitle '><a href='/truvadaprep-review-questions'><span>Post-Training Review Questions</span></a></li></ul></div>
<span class='navBtn navOpenBtn'>Open</span></div>
    </div>

    <div id="siteSubWrapper">
        <!-- MAIN CONTENT -->

        <!-- Body Section -->
        <div id="mainContent" class="hcp-blue">
            <div class="homeContent">
    <div id="brandBoxLeft">
        <div class="leftContent float-left">
            <h1>TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication</h1>
            <p>This is a <b>Risk Evaluation and Mitigation Strategy</b> (REMS) Web site. TRUVADA for a PrEP indication&mdash;in combination with safer sex practices&mdash;can help reduce the risk of sexually acquired <nobr>HIV-1</nobr> infection as part of a comprehensive HIV-1 prevention strategy in adults at high risk. TRUVADA for a PrEP indication does not replace existing prophylaxis strategies. <br /> <a href="/pre-exposure-prophylaxis" id="lnk-review-factors">Review factors that can help healthcare providers identify individuals at high risk for sexually acquired HIV-1 and important prescribing considerations</a></p>
            <br />
            <p><a href="#" id="openREMSSlider" class="openSlider linkArrow">Review the online training for prescribers</a></p>
            <p><a href="https://itookthetraining.com/" id="ReportCompletionTraining" class="linkArrow" target="_blank">Report completion of training for TRUVADA for a PrEP indication</a></p>
            <p><a href="https://preregister.truvadakabsurvey.com/" id="ParticipateKABSurvey" class="linkArrow" target="_blank">Participate in a Knowledge, Attitude, and Behavior (KAB) survey to assess the use and understanding of TRUVADA for PrEP</a></p>
        
        </div>
        <div class="rightContent float-left">
            <h2>REMS Information</h2>
            <p>A Risk Evaluation and Mitigation Strategy (REMS) is a strategy to manage known or potential serious risks associated with a drug product and is required by the Food and Drug Administration (FDA) to ensure that the benefits of the drug outweigh its risks.</p>
            <p>To make sure TRUVADA for a PrEP indication is prescribed and taken safely, Gilead has worked with the FDA to develop materials for the REMS program to educate and inform healthcare providers and uninfected individuals at high risk for acquiring HIV-1.</p>
            <p><a class="linkArrow" href="/truvadaprep-resources" id="access-rems-resources">Access REMS resources </a></p>
       
        </div>
        
    
    </div>
    <div id="brandBoxRight">
<h2 class="rightRailTitle">REMS Center</h2>

<div class="right-callout">
    <h3>Materials</h3>
    <a href="/truvadaprep-resources" class="right-rail dhpic" id="rightrail-link-to-resources">
        <span>Download important materials for healthcare providers and uninfected individuals about TRUVADA for a PrEP indication</span>
        <img alt="" src="/Content/img/rems/link_arrow.gif" />
    </a>
</div>

<div class="right-callout">
    <h3>Post-Training Review Questions</h3>
    <a href="/truvadaprep-review-questions" class="right-rail">
        <span>Assess your knowledge of TRUVADA for a PrEP indication by answering <br /> a series of review questions</span>
        <img alt="" src="/Content/img/rems/link_arrow.gif" />
    </a>
</div>    </div>
<div id="slideShowREMS" class="interstitialpopup hcp-blue">
    <div class="interstitialbody">
        <div class="interstitialTop"></div>
        <div class="interstitialContent">
            <a class="interstitialcancelbutton closePopup slidesClose" title="Close the layer"><span class="displace">Close the layer</span></a>
            <div id="slideShow">
                <div class="slides_container">
                    <!-- Slide 1 -->
                    <div id="firstSlide" class="slide" >
                        <h2>TRUVADA<sup>&reg;</sup> for a Pre-exposure<br />Prophylaxis (PrEP) Indication</h2>
                        <p><b>Healthcare Provider Training</b></p>
                    </div>

                    <!-- Slide 2 -->
                    <div class="slide">
                        <h2>Pre-Exposure Prophylaxis (PrEP) Indication</h2>
                        <ul>
                            <li>TRUVADA (emtricitabine/tenofovir disoproxil fumarate) is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired <nobr>HIV-1</nobr> infection in adults at high risk. This indication is based on clinical trials in men who have sex with men (MSM) at high risk for HIV-1 infection and in heterosexual serodiscordant couples.</li>
                        </ul>
                    </div>
                    
                    <!-- Slide 3 -->
                    <div class="slide">
                        <h2>Factors to Help Identify Individuals at High Risk</h2>
                        <ul>
                            <li>Has partner known to be HIV-1 infected, <i>or</i></li>
                            <li>Engages in sexual activity within a high prevalence area or social network and one or more of the following:
                                <ul>
                                    <li>Inconsistent or no condom use</li>
                                    <li>Diagnosis of sexually transmitted infections</li>
                                    <li>Exchange of sex for commodities (such as money, shelter, food, or drugs)</li>
                                    <li>Use of illicit drugs or alcohol dependence</li>
                                    <li>Incarceration</li>
                                    <li>Partner(s) of unknown HIV-1 status with any of the factors listed above</li>
                                </ul>
                            </li>
                        </ul>
                    </div>
                    
                    <!-- Slide 4 -->
                    <div class="slide">
                        <h2>When Prescribing TRUVADA for a PrEP Indication, Healthcare Providers MUST:</h2>
                        <ul>
                            <li>Prescribe TRUVADA as part of a comprehensive prevention strategy because TRUVADA is not always effective in preventing the acquisition of HIV-1 infection</li>
                            <li>Counsel all uninfected individuals to strictly adhere to the recommended daily TRUVADA dosing schedule because the effectiveness of TRUVADA in reducing the risk of acquiring HIV-1 infection is strongly correlated with adherence and measurable drug levels</li>
                            <li>
                                Confirm a negative HIV-1 test immediately prior to initiating TRUVADA for a PrEP indication. If clinical signs or symptoms consistent with acute viral infection are present and recent (<1 month) exposures are suspected, 
                                <ul>
                                    <li>delay starting PrEP for at least 1 month and reconfirm HIV-1 status, or</li>
                                    <li>use a test approved by the FDA as an aid in the diagnosis of HIV-1 infection, including acute or primary HIV-1 infection</li>
                                </ul>
                            </li>
                            <li>
                                While using TRUVADA for a PrEP indication, HIV-1 screening tests should be repeated at least every 3 months
                                <ul>
                                    <li>If symptoms consistent with acute HIV-1 infection develop following a potential exposure event, TRUVADA for a PrEP indication should be discontinued until negative infection status is confirmed using a test approved by the FDA as an aid in the diagnosis of HIV-1 infection, including acute or primary HIV-1 infection</li>
                                </ul>
                            </li>
                        </ul>
                    </div>
                    
                    <!-- Slide 5 -->
                    <div class="slide">
                        <h2>BOXED WARNING</h2>
                        <ul>
                            <li>TRUVADA used for a PrEP indication must only be prescribed to individuals confirmed to be HIV negative immediately prior to initiating and periodically (at least every 3 months) during use. Drug-resistant HIV-1 variants have been identified with the use of TRUVADA for a PrEP indication following undetected acute HIV-1 infection. Do not initiate TRUVADA for a PrEP indication if signs or symptoms of acute HIV-1 infection are present unless negative infection status is confirmed</li>
                        </ul>
                    </div>
                    
                    <!-- Slide 6 -->
                    <div class="slide">
                        <h2>BOXED WARNING (Continued)</h2>
                        <ul>
                            <li>Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including VIREAD, a component of TRUVADA</li>
                            <li>TRUVADA is not approved for the treatment of chronic hepatitis B virus (HBV) infection. Severe acute exacerbations of hepatitis B have been reported in patients infected with HBV who have discontinued TRUVADA. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are infected with HBV and discontinue TRUVADA. If appropriate, initiation of anti-hepatitis B therapy may be warranted</li>
                        </ul>
                    </div>
                    
                    <!-- Slide 7 -->
                    <div class="slide">
                        <h2>Why Use TRUVADA for a PrEP Indication?</h2>
                        <ul>
                            <li>By inhibiting HIV-1 from replicating as it enters the body, TRUVADA for a PrEP indication works to prevent the virus from establishing permanent infection. However, TRUVADA should not be seen as the first line of defense against HIV-1 infection</li>
                            <li>Because TRUVADA is not always effective in preventing the acquisition of HIV-1 infection, TRUVADA for a PrEP indication must be used in combination with a comprehensive prevention strategy that includes safer sex practices, such as regular and correct condom use, regular HIV testing for themselves (and their sexual partners), and other proven HIV prevention methods to safely and effectively reduce the risk of acquiring HIV-1 infection
                                <ul>
                                    <li>TRUVADA for a PrEP indication must only be prescribed to uninfected individuals at high risk who are confirmed to be HIV-1 negative</li>
                                    <li>Uninfected individuals who are prescribed TRUVADA for a PrEP indication should not miss any doses. Missing doses may increase the risk of acquiring HIV-1 infection</li>
                                </ul>
                            </li>
                        </ul>
                    </div>
                    
                    <!-- Slide 8 -->
                    <div class="slide">
                        <h2>Key Findings of the TRUVADA for a PrEP Indication Studies: The iPrEx Trial</h2>
                        <ul>
                            <li>In one clinical trial of TRUVADA for a PrEP indication, TRUVADA was shown to reduce the risk of HIV-1 acquisition by 42% for high risk men who have sex with men who also received comprehensive prevention services, including monthly HIV-1 testing, condom provision, counseling, and management of other sexually transmitted infections</li>
                            <li>In a post-hoc case control study of plasma and intracellular drug levels in about 10% of clinical trial subjects, risk reduction appeared to be the greatest in subjects with detectable intracellular tenofovir. Efficacy was therefore strongly correlated with adherence</li>
                            <li>Because of the intensive risk reduction counseling provided as part of the trial, self-reported risk behavior among the subjects in this clinical trial declined overall during the trial, both in terms of decreases in the number of sexual partners and increases in condom use</li>
                        </ul>
                    </div>
                    
                    <!-- Slide 9 -->
                    <div class="slide">
                        <h2>Key Findings of the TRUVADA for a PrEP Indication Studies: The Partners PrEP Trial </h2>
                        <ul>
                            <li>In another clinical trial of TRUVADA for a PrEP indication, TRUVADA was shown to reduce HIV-1 acquisition by 75% in uninfected individuals in stable heterosexual serodiscordant relationships who also received comprehensive prevention services, including monthly HIV testing, evaluation of adherence, assessment of sexual behavior, and safety evaluations</li>
                            <li>In a post-hoc case control study of plasma drug levels in about 10% of study subjects, risk reduction appeared to be the greatest in subjects with detectable plasma tenofovir. Efficacy was therefore strongly correlated with adherence. Risk reduction increased further in subjects with detectable plasma tenofovir</li>
                        </ul>
                    </div>
                    
                    <!-- Slide 10 -->
                    <div class="slide">
                        <h2>Important Safety Information: Comprehensive Management to Reduce the Risk of Acquiring HIV-1 Infection</h2>
                        <ul>
                            <li>Prescribe TRUVADA for PrEP only as part of a comprehensive prevention strategy that includes other prevention measures, such as safer sex practices, because TRUVADA for a PrEP indication is not always effective in preventing the acquisition of HIV-1 infection
                                <ul>
                                    <li>Counsel uninfected individuals about safer sex practices that include consistent and correct use of condoms, knowledge of their HIV-1 status and that of their partner(s), and regular testing for other sexually transmitted infections that can facilitate HIV-1 transmission (such as syphilis and gonorrhea)</li>
                                    <li>Inform uninfected individuals about and support their efforts in reducing sexual risk behavior</li>
                                </ul>
                            </li>
                        </ul>
                    </div>
                    
                    <!-- Slide 11 -->
                    <div class="slide">
                        <h2>Important Safety Information: Comprehensive Management to Reduce the Risk of Acquiring HIV-1 Infection</h2>
                        <ul>
                            <li>Prescribe TRUVADA to reduce the risk of acquiring HIV-1 infection only in individuals confirmed to be HIV negative
                                <ul>
                                    <li>HIV-1 resistance substitutions may emerge in individuals with undetected HIV-1 infection who are taking only TRUVADA, because TRUVADA alone does not constitute a complete regimen for HIV-1 treatment; therefore, care should be taken to minimize drug exposure in HIV-infected individuals
                                        <ul>
                                            <li>Many HIV-1 tests, such as rapid tests, detect anti-HIV antibodies and may not identify HIV-1 during the acute stage of infection. Prior to initiating TRUVADA for a PrEP indication, evaluate seronegative individuals for current or recent signs or symptoms consistent with acute viral infections (e.g., fever, fatigue, myalgia, skin rash, etc.) and ask about potential exposure events (e.g., unprotected, or condom broke during sex with an HIV-1 infected partner) that may have occurred within the last month</li>
                                        </ul>
                                    </li>
                                </ul>
                            </li>
                        </ul>
                    </div>
                    
                    <!-- Slide 12 -->
                    <div class="slide">
                        <h2>Important Safety Information: Comprehensive Management to Reduce the Risk of Acquiring HIV-1 Infection</h2>
                        <ul>
                            <li>Confirm a negative HIV-1 test immediately prior to initiating TRUVADA for a PrEP indication. If clinical signs or symptoms consistent with acute viral infection are present and recent (<1 month) exposures are suspected,
                                <ul>
                                    <li>delay starting PrEP for at least 1 month and reconfirm HIV-1 status or</li>
                                    <li>use a test approved by the FDA as an aid in the diagnosis of HIV-1 infection, including acute or primary HIV-1 infection</li>
                                </ul>
                            </li>
                            <li>While using TRUVADA for a PrEP indication, HIV-1 screening tests should be repeated at least every 3 months
                                <ul>
                                    <li>If symptoms consistent with acute HIV-1 infection develop following a potential exposure event, PrEP should be discontinued until negative infection status is confirmed using a test approved by the FDA as an aid in the diagnosis of HIV-1 infection, including acute or primary HIV-1 infection</li>
                                </ul>
                            </li>
                        </ul>
                    </div>
                    
                    <!-- Slide 13 -->
                    <div class="slide">
                        <h2>Important Safety Information: Comprehensive Management to Reduce the Risk of Acquiring HIV-1 Infection</h2>
                        <ul>
                            <li>Counsel uninfected individuals to strictly adhere to the recommended daily TRUVADA dosing schedule. The effectiveness of TRUVADA in reducing the risk of acquiring HIV-1 infection is strongly correlated with adherence and measurable drug levels</li>
                        </ul>
                    </div>
                    
                    <!-- Slide 14 -->
                    <div class="slide">
                        <h2>Important Safety Information: Additional Warnings and Precautions</h2>
                        <p>New Onset or Worsening Renal Impairment</p>
                        <ul>
                            <li>Can include acute renal failure and Fanconi syndrome</li>
                            <li>Assess estimated creatinine clearance (CrCl) before prescribing treatment with TRUVADA and periodically during therapy with TRUVADA</li>
                            <li>In individuals  at risk of renal impairment, monitor estimated  CrCl,  serum phosphorus, urine glucose and urine protein before prescribing TRUVADA and periodically while TRUVADA is being used</li>
                        </ul>
                    </div>
                    
                    <!-- Slide 15 -->
                    <div class="slide">
                        <h2>Important Safety Information: Additional Warnings and Precautions</h2>
                        <p>New Onset or Worsening Renal Impairment</p>
                        <ul>
                            <li>Avoid administering TRUVADA with concurrent or recent use of nephrotoxic drugs. Cases of acute renal failure, some requiring hospitalization and renal replacement therapy have been reported after initiation of high dose or multiple NSAIDs in patients with risk factors for renal dysfunction; consider alternatives to NSAIDs in these patients
                            <li>
                                Do not use TRUVADA for a PrEP indication in HIV-1 uninfected individuals with an estimated CrCl below 60 mL/min
                                <ul>
                                    <li>If a decrease in estimated CrCl is observed in uninfected individuals while using TRUVADA for a PrEP indication, evaluate potential causes and re-assess potential risks and benefits of continued use</li>
                                </ul>
                            </li>
                        </ul>
                    </div>
                    
                    <!-- Slide 16 -->
                    <div class="slide">
                        <h2>Important Safety Information: Additional Warnings and Precautions</h2>
                        <p>Bone effects</p>
                        <ul>
                            <li>Decreases in bone mineral density (BMD) and mineralization defects, including osteomalacia, have been seen in patients treated with tenofovir disoproxil fumarate. Consider assessment of BMD in individuals with a history of pathologic fracture or other risk factors for osteoporosis or bone loss</li>
                            <li>Persistent or worsening bone pain, pain in extremities, fractures and/or muscular pain or weakness may be manifestations of proximal renal tubulopathy and should prompt an evaluation of renal function in at-risk patients</li>
                        </ul>
                    </div>
                    
                    <!-- Slide 17 -->
                    <div class="slide">
                        <h2>Important Safety Information: Additional Warnings and Precautions</h2>
                        <p>Redistribution/accumulation of body fat</p>
                        <ul>
                            <li>Observed in patients receiving antiretroviral therapy for treatment of HIV-1 infection</li>
                        </ul>
                        <p>HBV Infection</p>
                        <ul>
                            <li>It is recommended that all individuals be tested for the presence of chronic HBV before initiating TRUVADA</li>
                            <li>HBV-uninfected individuals should be offered vaccination</li>
                        </ul>
                        <p>Coadministration with other products</p>
                        <ul>
                            <li>Do not use TRUVADA with drugs containing emtricitabine or tenofovir disoproxil fumarate, with drugs containing lamivudine, or with adefovir dipivoxil</li>
                        </ul>
                    </div>
                    
                    <!-- Slide 18 -->
                    <div class="slide">
                        <h2>Important Safety Information: Use of TRUVADA for a PrEP Indication in Specific Populations</h2>
                        <p>Pregnancy</p>
                        <ul>
                            <li>There are no adequate and well controlled trials in pregnant women</li>
                            <li>TRUVADA should be used during pregnancy only if clearly needed</li>
                            <li>If an uninfected individual becomes pregnant while taking TRUVADA for a PrEP indication, careful consideration should be given to whether the use of TRUVADA should be continued, taking into account the potential increased risk of HIV infection during pregnancy*</li>
                            <li>A pregnancy registry is available. Enroll pregnant women taking TRUVADA for a PrEP indication by calling 1-800-258-4263</li>
                        </ul>
                        <p> <span class="footnote">*Gray RH, et al. Lancet. 2005;366(9492):1182-1188.</span></p>
                    </div>
                    
                    <!-- Slide 19 -->
                    <div class="slide">
                        <h2>Important Safety Information: Use of TRUVADA for a PrEP Indication in Specific Populations</h2>
                        <p>Nursing Mothers</p>
                        <ul>
                            <li>The components of TRUVADA are excreted in breast milk. Because the risks to the infant are not known, mothers taking TRUVADA for a PrEP indication should be instructed not to breastfeed. If an uninfected individual acquires HIV-1 infection, it is recommended that she not breastfeed to avoid risking postnatal transmission of HIV-1</li>
                        </ul>
                        <p>Pediatrics</p>
                        <ul>
                            <li>TRUVADA for a PrEP indication is based on trials in adults</li>
                        </ul>
                    </div>
                    
                    <!-- Slide 20 -->
                    <div class="slide">
                        <h2>Important Safety Information: Confirming and Regularly Reconfirming Negative HIV-1 Status</h2>
                        <ul>
                            <li>TRUVADA should be used to reduce the risk of acquiring HIV-1 infection only in individuals confirmed to be HIV-1 negative
                                <ul>
                                    <li>A negative HIV-1 status should be confirmed before prescribing TRUVADA for a PrEP indication</li>
                                    <li>Individuals should be regularly tested (at least every 3 months) while taking TRUVADA for a PrEP indication to reconfirm that they are HIV-1 negative</li>
                                    <li>If symptoms consistent with acute HIV-1 infection develop following a potential exposure event, PrEP should be discontinued until negative infection status is confirmed using a test approved by the FDA as an aid in the diagnosis of HIV-1, including acute or primary HIV-1 infection</li>
                                </ul>
                            </li>
                        </ul>
                    </div>
                    
                    <!-- Slide 21 -->
                    <div class="slide">
                        <h2>Important Safety Information: Confirming and Regularly Reconfirming Negative HIV-1 Status</h2>
                        <p>Potential for Resistance in Undetected Acute HIV-1 Infection</p>
                        <ul>
                            <li>It is important to be alert to the signs of potential acute HIV-1 infection when prescribing TRUVADA for a PrEP indication. These include fever, headache, fatigue, arthralgia, vomiting, myalgia, diarrhea, pharyngitis, rash, night sweats, and cervical and inguinal adenopathy </li>
                            <li>
                                HIV-1 resistance mutations may emerge in individuals with undetected HIV-1 infection who are taking TRUVADA for a PrEP indication
                                <ul>
                                    <li>Although TRUVADA is active against HIV-1, TRUVADA alone does not constitute a complete treatment regimen for HIV-1 infection</li>
                                    <li>HIV-1 infected patients taking TRUVADA must take it with other antiretroviral agents to fully suppress virus replication and avoid the development of resistance</li>
                                </ul>
                            </li>
                        </ul>
                    </div>
                    
                    <!-- Slide 22 -->
                    <div class="slide">
                        <h2>Important Safety Information: Drug Interactions and Common Adverse Events</h2>
                        <p>Drug Interactions</p>
                        <ul>
                            <li>Coadministration of TRUVADA with drugs that reduce renal function or compete for active tubular secretion may increase concentrations of tenofovir</li>
                            <li>For further details about TRUVADA drug interactions, please see the <a href="http://www.gilead.com/~/media/Files/pdfs/medicines/hiv/truvada/truvada_pi.pdf" target="_blank" id="PIDownload">Prescribing Information</a></li>
                        </ul>
                        <p>Common Adverse Reactions </p>
                        <ul>
                            <li>In HIV-1 uninfected individuals in PrEP trials, adverse reactions that were reported by more than 2% of TRUVADA subjects and more frequently than by placebo subjects were headache, abdominal pain and decreased weight</li>
                        </ul>
                    </div>
                    
                    <!-- Slide 23 -->
                    <div class="slide">
                        <h2>Additional Educational Materials</h2>
                        <ul>
                            <li>
                                Agreement Form for Initiating TRUVADA for Pre-exposure Prophylaxis (PrEP) 
                                <ul>
                                    <li>Designed for prescribers to use with uninfected individuals to facilitate discussion of appropriate use of TRUVADA for a PrEP indication</li>
                                    <li>Form covers safety risks associated with use of TRUVADA for a PrEP indication, the importance of adherence to the recommended daily dosing regimen, regular assessment of HIV-1 test results, and screening for sexually transmitted infections</li>
                                </ul>
                            </li>
                            <li>
                                Checklist for Prescribers: Initiation of TRUVADA for Pre-exposure Prophylaxis (PrEP)
                                <ul>
                                    <li>Checklist of key components for prescribers to consider before starting an uninfected individual on TRUVADA for a PrEP indication</li>
                                    <li>Checklist items include confirming a negative HIV-1 test result, screening for signs or symptoms of acute HIV-1 infection, counseling on safety risks and importance of adherence, and other components to ensure a comprehensive prevention strategy</li>
                                </ul>
                            </li>
                            <li>Copies are available from <a href="http://www.truvadapreprems.com" target="_blank" id="TruvadaPrEPREMSPop1">www.TRUVADApreprems.com</a> or by filling out the postage paid, business reply card at the back of the Training Guide for Healthcare Providers</li>
                        </ul>
                    </div>

                    <!-- Slide 24 -->
                    <div class="slide">
                        <h2>Additional Educational Materials</h2>
                        <ul>
                            <li>Additional educational materials can be reviewed and downloaded at <a href="http://www.truvadapreprems.com" target="_blank" id="TruvadaPrEPREMSPop2">www.TRUVADApreprems.com</a></li>
                            <li>Please confirm completion of training by going to <a href="http://www.truvadapreprems.com" target="_blank" id="TruvadaPrEPREMSPop3">www.TRUVADApreprems.com</a> or by filling out the postage paid, business reply card at back of the Training Guide for Healthcare Providers </li>
                            <li>Gilead is conducting a survey to fulfill an FDA-required Risk Evaluation and Mitigation Strategy (REMS) program to assess prescribersâ€™ knowledge regarding important safety information associated with the use of TRUVADA for a PrEP indication. To participate, please go to <a href="http://www.truvadapreprems.com" target="_blank" id="TruvadaPrEPREMSPop4">www.TRUVADApreprems.com</a>  or fill out the postage paid, business reply card at the back of the Training Guide for Healthcare Providers</li>
                        </ul>
                    </div>
                    
                    <!-- Slide 25 -->
                    <div class="slide noPagination">
                        <h2>Assess Your Knowledge of TRUVADA for a PrEP Indication</h2>
                        <div class="linkContainer">
                            <br />
                            <div class="linkBox"><a id="assessKnowledge" href="/truvadaprep-review-questions/true" class="boxedLink" >Go to review questions</a></div>
                            <div class="linkBox"><a id="advanceInputScreen" class="boxedLink" href="#">No thanks</a></div>
                            <p><a href="https://itookthetraining.com/" target="_blank" class="linkArrow" id="ReportCompletionTrainingPop">Report completion of training for TRUVADA for a PrEP indication</a></p>
                            <p><a href="https://preregister.truvadakabsurvey.com/" target="_blank" class="linkArrow" id="ParticipateKABSurveyPop">Participate in a Knowledge, Attitude, and Behavior (KAB) survey to assess the use and understanding of TRUVADA for PrEP</a></p>
                            <br />
                        </div>
                    </div>

                    <!-- Slide 26 -->
                    <div class="slide noPagination">
                        <h2>To help Gilead and the FDA understand who has viewed this training, please tell us the following</h2>
                        
<form action="/Utilities/AssessmentResolved" id="trainingResolvedform" method="post">                            <div class="formCol">
                                <label for="Specialty" >Your Specialty:</label>
                                <select id="Specialty" name="Specialty"><option value="">Indicate your specialty</option>
<option value="Internal medicine">Internal medicine</option>
<option value="Family practice">Family practice</option>
<option value="General medicine">General medicine</option>
<option value="Infectious diseases">Infectious diseases</option>
<option value="Obstetrics/gynecology">Obstetrics/gynecology</option>
<option value="Addiction medicine">Addiction medicine</option>
<option value="Other">Other</option>
</select>
                                <span id="SpecialtyError" class="fieldError"></span>
                            </div>
                            <div class="formCol">
                               <label for="Profession">Your Profession:</label>
                                <select id="Profession" name="Profession"><option value="">Select your profession</option>
<option value="MD">MD</option>
<option value="PA">PA</option>
<option value="NP">NP</option>
<option value="Other">Other</option>
</select>
                                <span id="ProfessionError" class="fieldError"></span>
                            </div>
                            <div class="formCol formColDouble">
                               <label for="ZipCode">Zip Code:</label><br />
                                <input class="field field-sample-text" id="ZipCode" maxlength="5" name="ZipCode" placeholder="Your office Zip Code" title="Your office zip code" type="text" value="" />
                                <span id="ZipCodeError" class="fieldError"></span>
                            </div>                            
                            <div class="linkContainer">
                                <div class="linkBox"><a id="trainingResolvedSubmit" href="#" class="boxedLink" >Submit</a></div>
                                <div class="linkBox"><a id="trainingNoThanks" class="interstitialcancelbutton boxedLink" href="#">No thanks</a></div>
                            </div>
                            <p><a href="https://itookthetraining.com/" target="_blank" class="linkArrow" id="ReportCompletionTrainingPop">Report completion of training for TRUVADA for a PrEP indication</a></p>
                            <p><a href="https://preregister.truvadakabsurvey.com/" target="_blank" class="linkArrow" id="ParticipateKABSurveyPop">Participate in a Knowledge, Attitude, and Behavior (KAB) survey to assess the use and understanding of TRUVADA for PrEP</a></p>
</form>                        <div id="hideNext"></div>
                        <div id="hidePrev"></div>
                    </div>
                    
                    <!-- Slide 27 -->
                    <div class="slide noPagination">
                        <h2>Thank you</h2>
                        <br />
                        <div class="linkBox"><a id="" class="boxedLink interstitialcancelbutton" href="#">Close</a></div>
                    </div>
                </div>
            </div>
        </div>
    </div>
    <div class="interstitialBot">
    </div>
</div></div>




            <!-- ISI Section -->
            <div id="isi-content">
                
            </div>
        </div>
        <!-- END of Body Section -->

        <!-- Footer -->

<div id="footer" class="global-foot-copy">
    <img id="footer-logo" src="/Content/img/global/lgo_gilead.png" alt="Gilead" />
    <a href="/sitemap">Site Map</a>

    <p>The information on this site is intended for audiences 18 years of age or older in the United States only. The content on this site may not apply to non-US audiences as regulatory control, legal requirements and/or medical practices may vary in other countries. Read the full site disclaimer at www.gilead.com/terms_of_use.</p>
          
    <p>TRUVADA, the TRUVADA Logo, GILEAD, the GILEAD Logo, and GSI, are trademarks of Gilead Sciences, Inc., or its related companies.  All other marks referenced herein are the property of their respective owners.</p>

    <p>&copy;2014 Gilead Sciences, Inc. All rights reserved. 06/14</p>
</div>
        <!-- define sections -->
        

    </div>

</div>
<div id="interstitialCertifyhcp" class="interstitialpopup hcp-blue">
    <div class="interstitialbody" >
        <div class="interstitialTop"></div>
        <div class="interstitialContent">
            <p>The information on this site is intended for adult residents<br />of the United States.</p> 
            <div class="linkContainer">
                <a id="yes" href="#" class="boxedLink" >OK</a>
            </div>
        </div>
        <div class="interstitialBot"></div>
    </div>
</div><!-- Leaving Interstitial HTML block -->
<div id="leaveSiteQ" class="interstitialpopup hcp-blue">
    <div class="interstitialTop"></div>
    <div class="interstitialContent">
        <a class="interstitialcancelbutton closePopup" title="Close the layer"><span class="displace">Close the layer</span></a>
        <h3>You Are Now Leaving</h3>
        <p>By following this link, you are now leaving www.TRUVADApreprems.com. <br /> These sites are not controlled by Gilead Sciences, Inc. Gilead Sciences, Inc. is not responsible for their content or your use of them.</p>
        <div class="linkContainer">
            <div class="linkBox"><a class="interstitialokbutton boxedLink" >Leave Site</a></div>
            <div class="linkBox"><a class="interstitialcancelbutton">Go Back</a></div>
        </div>
    </div>
    <div class="interstitialBot"></div>
</div>

    <!-- View specific scripts before loading the javascripts files - Optional -->
    

    <!-- this partial view will contain all the javascript includes -->

<!-- Grab Google CDN's jQuery, with a protocol relative URL; fall back to local if offline -->
<script src="//ajax.googleapis.com/ajax/libs/jquery/1.7.1/jquery.min.js"></script>
<script>    window.jQuery || document.write('<script src="/Content/js/jquery-1.7.1.min.js"><\/script>')</script>

    <!-- Core application script -->
    <script src="/Content/js/jscompressed.js"></script>

    <!-- View specific scripts after loading the javascripts files - Optional -->
    
            <!-- Place this render call where appropriate -->
            <script type="text/javascript">

                (function () {
                    // interstitial logic - if cookie has not been created yet, block UI and prompt user
                    if (TP.getCookie('hcp') === null) {
                        TP.block('hcp');
                    }
                })();

            </script>
            
    <script type="text/javascript">
        (function () {
            TP.initializeSlider();
        })();
    </script>
 
        

</body>
</html>";i:2;s:4:"5319";}